

Evidence-based Clinical Practice
Hepatocellular Carcinoma: The
Society of Hepatology 2013 update

Hepatology Research

45,

DOI: 10.1111/hepr.12464

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Impact of the branched-chain amino acid to tyrosine ratio and branched-chain amino acid granule therapy in patients with hepatocellular carcinoma: A propensity score analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1412-1419. | 1.4 | 24 |
| 2 | Management before hepatectomy for hepatocellular carcinoma with cirrhosis. <i>World Journal of Hepatology</i> , 2015, 7, 2292. | 0.8 | 13 |
| 3 | General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer Study Group of Japan. <i>Digestive Diseases</i> , 2015, 33, 765-770. | 0.8 | 229 |
| 4 | Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging. <i>Digestive Diseases</i> , 2015, 33, 735-744. | 0.8 | 19 |
| 5 | Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria). <i>Digestive Diseases</i> , 2015, 33, 751-758. | 0.8 | 167 |
| 6 | Fatal Diaphragmatic Hernia following Radiofrequency Ablation for Hepatocellular Carcinoma: A Case Report and Literature Review. <i>Case Reports in Oncology</i> , 2015, 8, 238-245. | 0.3 | 18 |
| 7 | Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe. <i>Liver Cancer</i> , 2015, 4, 85-95. | 4.2 | 83 |
| 8 | A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 7-17. | 4.5 | 232 |
| 9 | Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 8271. | 1.4 | 33 |
| 10 | Pathological complete response after percutaneous isolated hepatic perfusion in hepatocellular carcinoma with portal vein tumor thrombosis: a case report. <i>Surgical Case Reports</i> , 2016, 2, 50. | 0.2 | 0 |
| 11 | Heterogeneity and Subclassification of Barcelona Clinic Liver Cancer Stage B. <i>Liver Cancer</i> , 2016, 5, 91-96. | 4.2 | 32 |
| 12 | Assessment of Preoperative Liver Function in Patients with Hepatocellular Carcinoma â€” The Albumin-Indocyanine Green Evaluation (ALICE) Grade. <i>PLoS ONE</i> , 2016, 11, e0159530. | 1.1 | 60 |
| 13 | Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. <i>World Journal of Gastroenterology</i> , 2016, 22, 7289. | 1.4 | 138 |
| 14 | Early Decreases in Î±-Fetoprotein and Des-Î³-carboxy Prothrombin Predict the Antitumor Effects of Hepatic Transarterial Infusion Chemotherapy with Cisplatin (CDDP) Powder in Patients with Advanced Hepatocellular Carcinoma. <i>Internal Medicine</i> , 2016, 55, 2163-2171. | 0.3 | 3 |
| 15 | Ongoing challenges in the diagnosis of hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 451-463. | 1.4 | 5 |
| 16 | Avoiding Pitfalls in the Interpretation of Gadoteric Acidâ€”Enhanced Magnetic Resonance Imaging. <i>Seminars in Ultrasound, CT and MRI</i> , 2016, 37, 561-572. | 0.7 | 12 |
| 17 | Reply to: â€œLocal recurrence is not equal to local disseminationâ€”after resection for hepatocellular carcinomaâ€” <i>Journal of Hepatology</i> , 2016, 65, 1062-1063. | 1.8 | 0 |
| 18 | Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 15447-15456. | 0.8 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Expanded Criteria for Resection: Are Current Guidelines Too Conservative?. <i>Current Hepatology Reports</i> , 2016, 15, 323-326. | 0.4 | 3 |
| 20 | Recent Trends in the Management of Hepatocellular Carcinoma with Special Emphasis on Treatment with Regorafenib and Immune Checkpoint Inhibitors. <i>Digestive Diseases</i> , 2016, 34, 714-730. | 0.8 | 7 |
| 21 | Contribution of Contrast-Enhanced Sonography With Perfluorobutane Microbubbles for Diagnosis of Recurrent Hepatocellular Carcinoma. <i>Journal of Ultrasound in Medicine</i> , 2016, 35, 1383-1391. | 0.8 | 8 |
| 22 | Highly sensitive alpha-fetoprotein, <i>Lens culinaris</i> agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection. <i>Hepatology Research</i> , 2016, 46, E130-5. | 1.8 | 52 |
| 23 | Hepatocellular carcinoma surgery outcomes in the developing world: A 20-year retrospective cohort study at the National Cancer Institute of Peru. <i>Heliyon</i> , 2016, 2, e00052. | 1.4 | 20 |
| 24 | Pathophysiology of recurrent hepatocellular carcinoma after radiofrequency ablation. <i>Hepatology Research</i> , 2017, 47, 23-30. | 1.8 | 34 |
| 25 | Hepatitis C virus reactivation due to antiemetic steroid therapy during treatment of hepatocellular carcinoma. <i>Journal of Infection and Chemotherapy</i> , 2017, 23, 323-325. | 0.8 | 6 |
| 26 | Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. <i>Lancet Oncology</i> , The, 2017, 18, e101-e112. | 5.1 | 123 |
| 27 | Loco-regional treatment of HCC: current status. <i>Clinical Radiology</i> , 2017, 72, 626-635. | 0.5 | 72 |
| 28 | Diagnosis of Hepatocellular Carcinoma with Non-Invasive Imaging: a Plea for Worldwide Adoption of Standard and Precise Terminology for Describing Enhancement Criteria. <i>Ultraschall in Der Medizin</i> , 2017, 38, 9-11. | 0.8 | 16 |
| 29 | Discrepant imaging findings of portal vein thrombosis with dynamic computed tomography and computed tomography during arterial portography in hepatocellular carcinoma: possible cause leading to inappropriate treatment selection. <i>Clinical Journal of Gastroenterology</i> , 2017, 10, 163-167. | 0.4 | 5 |
| 30 | Importance of Screening for Esophagogastric Varices in Naïve Hepatocellular Carcinoma Patients within Milan Criteria: Indicator for Liver Transplantation. <i>Digestive Surgery</i> , 2017, 34, 429-435. | 0.6 | 1 |
| 31 | Successful Treatment of Hepatocellular Carcinoma Complicated by Fanconi Anemia. <i>Case Reports in Gastroenterology</i> , 2017, 11, 29-35. | 0.3 | 0 |
| 32 | Should AFP (or Any Biomarkers) Be Used for HCC Surveillance?. <i>Current Hepatology Reports</i> , 2017, 16, 137-145. | 0.4 | 26 |
| 33 | Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib. <i>Oncology</i> , 2017, 92, 335-346. | 0.9 | 11 |
| 34 | C-Arm Cone Beam Computed Tomography Guidance for Radiofrequency Ablation in Hepatocellular Carcinoma. <i>Oncology</i> , 2017, 92, 142-152. | 0.9 | 10 |
| 35 | Cost-effectiveness of EOB-MRI for Hepatocellular Carcinoma in Japan. <i>Clinical Therapeutics</i> , 2017, 39, 738-750.e4. | 1.1 | 18 |
| 36 | Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. <i>Liver Cancer</i> , 2017, 6, 204-215. | 4.2 | 159 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Salvage hepatectomy for local recurrence of hepatocellular carcinomas offers survival comparable to that of matched patients who undergo primary hepatectomies. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1076-1082. | 0.5 | 2 |
| 38 | Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment. <i>Liver Cancer</i> , 2017, 6, 16-26. | 4.2 | 97 |
| 39 | Surgery and Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2017, 6, 44-50. | 4.2 | 42 |
| 40 | Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus. <i>Hepatology Research</i> , 2017, 47, 957-962. | 1.8 | 48 |
| 41 | Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. <i>Hepatology International</i> , 2017, 11, 317-370. | 1.9 | 1,537 |
| 42 | <scp>EASL</scp> and <scp>AASLD</scp> recommendations for the diagnosis of <scp>HCC</scp> to the test of daily practice. <i>Liver International</i> , 2017, 37, 1515-1525. | 1.9 | 102 |
| 43 | Diagnostic value of PIVKA-II in detecting hepatocellular carcinoma. <i>Future Virology</i> , 2017, 12, 259-267. | 0.9 | 4 |
| 44 | Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2017, 7, 244. | 1.6 | 14 |
| 45 | Survival in patients with Child-Pugh class C cirrhosis: Analysis of the liver transplant registry in Japan. <i>Hepatology Research</i> , 2017, 47, 1155-1164. | 1.8 | 16 |
| 46 | Screening and Surveillance of Hepatocellular Carcinoma. <i>Radiologic Clinics of North America</i> , 2017, 55, 1197-1209. | 0.9 | 28 |
| 47 | Non-Hypervascular Hypointense Hepatic Nodules during the Hepatobiliary Phase of Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI as a Risk Factor of Intrahepatic Distant Recurrence after Radiofrequency Ablation of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2017, 35, 574-582. | 0.8 | 13 |
| 48 | Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization. <i>Oncology Letters</i> , 2017, 14, 3028-3034. | 0.8 | 16 |
| 49 | Liver investigations: Updating on US technique and contrast-enhanced ultrasound (CEUS). <i>European Journal of Radiology</i> , 2017, 96, 65-73. | 1.2 | 30 |
| 50 | Is there a standard for surgical therapy of hepatocellular carcinoma in healthy and cirrhotic liver? A comparison of eight guidelines. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000129. | 1.1 | 17 |
| 51 | Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis. <i>Therapeutic Apheresis and Dialysis</i> , 2017, 21, 465-472. | 0.4 | 12 |
| 52 | Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm. <i>Liver Cancer</i> , 2017, 6, 185-188. | 4.2 | 11 |
| 53 | Characterization of Focal Liver Lesions using CEUS and MRI with Liver-Specific Contrast Media: Experience of a Single Radiologic Center. <i>Ultraschall in Der Medizin</i> , 2017, 38, 619-625. | 0.8 | 45 |
| 54 | Evaluation of the current guidelines for resection of hepatocellular carcinoma using the Appraisal of Guidelines for Research and Evaluation II instrument. <i>Journal of Hepatology</i> , 2017, 67, 991-998. | 1.8 | 26 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients. <i>Medicine (United States)</i> , 2017, 96, e7266. | 0.4 | 29 |
| 56 | Evaluation of sorafenib for advanced hepatocellular carcinoma with low α -fetoprotein in arrival time parametric imaging using contrast-enhanced ultrasonography. <i>Journal of Medical Ultrasonics (2001)</i> , 2017, 44, 101-107. | 0.6 | 13 |
| 57 | Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus. <i>European Radiology</i> , 2017, 27, 1448-1458. | 2.3 | 31 |
| 58 | Application of radiofrequency ablation for the treatment of intermediate-stage hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 695-700. | 1.4 | 23 |
| 59 | Surveillance of Hepatocellular Carcinoma by Magnetic Resonance Imaging With Liver-Specific Contrast. <i>JAMA Oncology</i> , 2017, 3, 446. | 3.4 | 3 |
| 60 | New Paradigm in Gastrointestinal Cancer Treatment. <i>Oncology</i> , 2017, 93, 1-8. | 0.9 | 3 |
| 61 | Overdiagnosis: An Understudied Issue in Hepatocellular Carcinoma Surveillance. <i>Seminars in Liver Disease</i> , 2017, 37, 296-304. | 1.8 | 29 |
| 62 | Surveillance for Hepatocellular Carcinoma Reduces Mortality: an Inverse Probability of Treatment Weighted Analysis. <i>Annals of Hepatology</i> , 2017, 16, 421-429. | 0.6 | 8 |
| 63 | Hepatocellular carcinoma: early-stage management challenges. <i>Journal of Hepatocellular Carcinoma</i> , 2017, Volume 4, 81-92. | 1.8 | 60 |
| 64 | Liver resection in cirrhosis. , 2017, , 1578-1586.e3. | | 0 |
| 65 | Prognostic Impact of Indocyanine Green Plasma Disappearance Rate in Hepatocellular Carcinoma Patients after Radiofrequency Ablation: A Prognostic Nomogram Study. <i>Internal Medicine</i> , 2017, 56, 1001-1007. | 0.3 | 3 |
| 66 | Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results. <i>Oncotarget</i> , 2017, 8, 59965-59976. | 0.8 | 22 |
| 67 | Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1201-1212. | 1.9 | 14 |
| 68 | Liver Transplantation for Intermediate-Stage Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 179-189. | 4.2 | 12 |
| 69 | Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS. <i>European Radiology</i> , 2018, 28, 4254-4264. | 2.3 | 54 |
| 70 | Prediction of major complications after hepatectomy using liver stiffness values determined by magnetic resonance elastography. <i>British Journal of Surgery</i> , 2018, 105, 1192-1199. | 0.1 | 15 |
| 71 | Current topics in the surgical treatments for hepatocellular carcinoma. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 137-146. | 1.2 | 30 |
| 72 | Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. <i>Liver Cancer</i> , 2018, 7, 104-119. | 4.2 | 95 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 182-236. | 1.8 | 6,153 |
| 74 | Liver resection for recurrent hepatocellular carcinoma to improve survivability: a proposal of indication criteria. <i>Surgery</i> , 2018, 163, 1250-1256. | 1.0 | 14 |
| 75 | Microvascular invasion of single small hepatocellular carcinoma ≤3 cm: Predictors and optimal treatments. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 197-203. | 1.2 | 40 |
| 76 | Laparoscopic liver resection for hepatocellular carcinoma in early and advanced cirrhosis. <i>Hpb</i> , 2018, 20, 521-529. | 0.1 | 26 |
| 77 | Liver resection of hepatocellular carcinoma in patients with portal hypertension and multiple tumors. <i>Hepatology Research</i> , 2018, 48, 433-441. | 1.8 | 14 |
| 78 | The Clinical Implications of Liver Resection Margin Size in Patients with Hepatocellular Carcinoma in Terms of Positron Emission Tomography Positivity. <i>World Journal of Surgery</i> , 2018, 42, 1514-1522. | 0.8 | 14 |
| 79 | Biomarker Discovery and Validation in HCC Diagnosis, Prognosis, and Therapy. <i>Molecular Pathology Library</i> , 2018, , 95-113. | 0.1 | 1 |
| 80 | Hepatocellular carcinoma. <i>Lancet, The</i> , 2018, 391, 1301-1314. | 6.3 | 3,878 |
| 81 | Stereotactically navigated percutaneous microwave ablation (MWA) compared to conventional MWA: a matched pair analysis. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2018, 13, 1991-1997. | 1.7 | 21 |
| 82 | A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy. <i>Oncology Letters</i> , 2018, 15, 4411-4422. | 0.8 | 24 |
| 83 | Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 381-403. | 0.8 | 92 |
| 84 | A systematic review of publications on charged particle therapy for hepatocellular carcinoma. <i>International Journal of Clinical Oncology</i> , 2018, 23, 423-433. | 1.0 | 33 |
| 85 | Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. <i>Radiotherapy and Oncology</i> , 2018, 129, 112-122. | 0.3 | 80 |
| 86 | Proposal for subclassification to select patients for hepatectomy with intermediate hepatocellular carcinoma and Child-Pugh A liver function. <i>Medicine (United States)</i> , 2018, 97, e11800. | 0.4 | 2 |
| 87 | Inspiration of liver resection for hepatocellular carcinoma associated with hepatic vein invasion, not inferior vena cava invasion. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 392-394. | 0.7 | 0 |
| 88 | Locoregional therapy as a bridge to liver transplantation for hepatocellular carcinoma within Milan criteria: from a transplant oncology viewpoint. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 134-135. | 0.7 | 4 |
| 89 | A scoring system to predict HBsAg seroclearance in hepatitis B and C coinfecting patients treated with interferon and ribavirin in an Asian cohort. <i>Medicine (United States)</i> , 2018, 97, e13383. | 0.4 | 5 |
| 90 | L-Carnitine for the Treatment of Overt Hepatic Encephalopathy in Patients with Advanced Liver Cirrhosis. <i>Journal of Nutritional Science and Vitaminology</i> , 2018, 64, 321-328. | 0.2 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 353-371. | 0.7 | 73 |
| 92 | Validation of the albuminâ€ndocyanine green evaluation model in patients with resected hepatocellular carcinoma and comparison with the albuminâ€bilirubin score. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2018, 26, 51-57. | 1.4 | 18 |
| 93 | Optimal management of patients with hepatocellular carcinoma treated with lenvatinib. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1095-1105. | 1.0 | 30 |
| 94 | von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C. <i>United European Gastroenterology Journal</i> , 2018, 6, 1401-1409. | 1.6 | 27 |
| 95 | Should We Abandon Current Hepatocellular Carcinoma Screening Practices?. <i>Gastroenterology</i> , 2018, 155, 972-974. | 0.6 | 9 |
| 96 | Management of Hepatocellular Carcinoma in Japan as a World-Leading Model. <i>Liver Cancer</i> , 2018, 7, 134-147. | 4.2 | 56 |
| 97 | A combination of the onâ€treatment <scp>FIB</scp>â€4 and alphaâ€fetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir. <i>Liver International</i> , 2018, 38, 1997-2005. | 1.9 | 13 |
| 98 | Hepatectomy versus stereotactic body radiotherapy for primary early hepatocellular carcinoma: A propensity-matched analysis in a single institution. <i>Surgery</i> , 2018, 164, 219-226. | 1.0 | 27 |
| 99 | Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept. <i>Scientific Reports</i> , 2018, 8, 9997. | 1.6 | 84 |
| 100 | The High-Sensitivity C-Reactive Protein/Albumin Ratio Predicts Long-Term Oncologic Outcomes after Curative Resection for Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2018, 7, 139. | 1.0 | 15 |
| 101 | The preliminary application of liver imaging reporting and data system (LI-RADS) with contrast-enhanced ultrasound (CEUS) on small hepatic nodules (â‰‰â‰‰2cm). <i>Journal of Cancer</i> , 2018, 9, 2946-2952. | 1.2 | 29 |
| 102 | Propensity scoreâ€matched comparison of nonâ€anatomical resection and radiofrequency ablation for hepatocellular carcinoma in patients with up to three tumours, each measuring up to 3 cm in diameter. <i>BJS Open</i> , 2018, 2, 213-219. | 0.7 | 3 |
| 103 | Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies. <i>BMC Cancer</i> , 2018, 18, 756. | 1.1 | 44 |
| 104 | A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. <i>Scientific Reports</i> , 2018, 8, 10434. | 1.6 | 32 |
| 105 | Prognostic value of subcutaneous adipose tissue volume in hepatocellular carcinoma treated with transcatheter intra-arterial therapy. <i>Cancer Management and Research</i> , 2018, Volume 10, 2231-2239. | 0.9 | 21 |
| 106 | Prognostic value of hsaâ€mirâ€299 and hsaâ€mirâ€7706 in hepatocellular carcinoma. <i>Oncology Letters</i> , 2018, 16, 815-820. | 0.8 | 10 |
| 107 | Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis. <i>Digestive Diseases</i> , 2018, 36, 314-321. | 0.8 | 10 |
| 108 | Liver volume-based prediction model stratifies risks for hepatocellular carcinoma in chronic hepatitis B patients on surveillance. <i>PLoS ONE</i> , 2018, 13, e0190261. | 1.1 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Percutaneous US/MRI Fusionâ€“guided Radiofrequency Ablation for Recurrent Subcentimeter Hepatocellular Carcinoma: Technical Feasibility and Therapeutic Outcomes. <i>Radiology</i> , 2018, 288, 878-886. | 3.6 | 68 |
| 110 | Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. <i>Liver Cancer</i> , 2019, 8, 121-129. | 4.2 | 159 |
| 111 | Multimodal radiofrequency ablation versus laparoscopic hepatic resection for the treatment of primary hepatocellular carcinoma within Milan criteria in severely cirrhotic patients: long-term favorable outcomes over 10Âyears. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2019, 33, 46-51. | 1.3 | 15 |
| 112 | Diabetes is associated with advanced fibrosis and fibrosis progression in non-genotype 3 chronic hepatitis C patients. <i>Digestive and Liver Disease</i> , 2019, 51, 142-148. | 0.4 | 1 |
| 113 | Ratio between estimated glomerular filtration rates of creatinine and cystatin C predicts overall survival in patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2019, 49, 153-163. | 1.8 | 17 |
| 114 | Optimal criteria for hepatocellular carcinoma diagnosis using CT in patients undergoing liver transplantation. <i>European Radiology</i> , 2019, 29, 1022-1031. | 2.3 | 9 |
| 115 | Reduced handgrip strength is predictive of poor survival among patients with liver cirrhosis: A sexâ€“stratified analysis. <i>Hepatology Research</i> , 2019, 49, 1414-1426. | 1.8 | 51 |
| 116 | Biomarkers <i>vs</i> imaging in the early detection of hepatocellular carcinoma and prognosis. <i>World Journal of Clinical Cases</i> , 2019, 7, 1367-1382. | 0.3 | 15 |
| 117 | B-Mode Ultrasonography versus Contrast-Enhanced Ultrasonography for Surveillance of Hepatocellular Carcinoma: A Prospective Multicenter Randomized Controlled Trial. <i>Liver Cancer</i> , 2019, 8, 271-280. | 4.2 | 48 |
| 118 | Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 721-730. | 3.7 | 105 |
| 119 | Prognostic profile of patients with nonâ€“viral hepatocellular carcinoma: A comparative study with hepatitis C virusâ€“related hepatocellular carcinoma using data mining analysis. <i>Oncology Letters</i> , 2019, 18, 227-236. | 0.8 | 6 |
| 120 | Contrast-enhanced US with Perfluorobutane for Hepatocellular Carcinoma Surveillance: A Multicenter Diagnostic Trial (SCAN). <i>Radiology</i> , 2019, 292, 638-646. | 3.6 | 30 |
| 121 | Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th) Tj ETQq0 0 0 rgBT /Overlock 10 Tf | 1.8 | 399 |
| 122 | Lgr5-mediated p53 Repression through PDCD5 leads to doxorubicin resistance in Hepatocellular Carcinoma. <i>Theranostics</i> , 2019, 9, 2967-2983. | 4.6 | 41 |
| 123 | Comparison of nonâ€“invasive liver reserve and fibrosis models: Implications for surgery and prognosis for hepatocellular carcinoma. <i>Hepatology Research</i> , 2019, 49, 1305-1315. | 1.8 | 12 |
| 124 | Early Detection of Pancreatic Cancer in Patients With Chronic Liver Disease Under Hepatocellular Carcinoma Surveillance. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2004-2010. | 1.4 | 6 |
| 125 | A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B. <i>Clinical Chemistry</i> , 2019, 65, 1543-1553. | 1.5 | 53 |
| 126 | Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma. <i>BMC Cancer</i> , 2019, 19, 1088. | 1.1 | 28 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Rapid Depletions of Subcutaneous Fat Mass and Skeletal Muscle Mass Predict Worse Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Cancers</i> , 2019, 11, 1206. | 1.7 | 38 |
| 128 | Prior hepatitis B virus infection as a co-factor of chronic hepatitis C patient survival after resection of hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2019, 19, 147. | 0.8 | 5 |
| 129 | A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2019, 3, 302-310. | 1.2 | 58 |
| 130 | Safety and effectiveness of multi-antenna microwave ablation-oriented combined therapy for large hepatocellular carcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986296. | 1.4 | 12 |
| 131 | Ultrasonography surveillance improves prognosis of patients with hepatocellular carcinoma. <i>Molecular and Clinical Oncology</i> , 2019, 11, 325-330. | 0.4 | 0 |
| 132 | Utility of scoring systems combining the product of tumor number and size with liver function for predicting the prognosis of patients with hepatocellular carcinoma after hepatectomy. <i>Oncology Letters</i> , 2019, 18, 3903-3913. | 0.8 | 4 |
| 133 | Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 625-651. | 0.4 | 8 |
| 134 | Validation of a novel model for the early detection of hepatocellular carcinoma. <i>Clinical Proteomics</i> , 2019, 16, 2. | 1.1 | 21 |
| 135 | Identification of Arterial Hyperenhancement in CT and MRI in Patients with Hepatocellular Carcinoma: Value of Unenhanced Images. <i>Korean Journal of Radiology</i> , 2019, 20, 236. | 1.5 | 12 |
| 136 | User and system pitfalls in liver imaging with LI-RADS. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 1673-1686. | 1.9 | 18 |
| 137 | Combined Albumin-Bilirubin Grade and Skeletal Muscle Mass as a Predictor in Liver Cirrhosis. <i>Journal of Clinical Medicine</i> , 2019, 8, 782. | 1.0 | 12 |
| 138 | Successful Treatment of Hepatocellular Carcinoma with Transcatheter Arterial Chemoembolization followed by Radical Liver Transplantation in a Patient with Severe Liver Damage. <i>Case Reports in Oncology</i> , 2019, 12, 289-296. | 0.3 | 0 |
| 139 | PET Imaging of Hepatocellular Carcinoma. <i>Current Radiology Reports</i> , 2019, 7, 1. | 0.4 | 0 |
| 140 | High serum interleukin-34 level is a predictor of poor prognosis in patients with non-viral hepatocellular carcinoma. <i>Hepatology Research</i> , 2019, 49, 1046-1053. | 1.8 | 21 |
| 141 | Skeletal muscle volume loss during transarterial chemoembolization predicts poor prognosis in patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2019, 49, 778-786. | 1.8 | 39 |
| 142 | Combination of Resection and Ablative Treatment for Hepatocellular Carcinoma: Usefulness of Complementary Radiofrequency Ablation. <i>Oncology</i> , 2019, 96, 242-251. | 0.9 | 8 |
| 143 | Hepatocellular carcinoma after direct-acting antiviral drug treatment in patients with hepatitis C virus. <i>JGH Open</i> , 2019, 3, 52-60. | 0.7 | 13 |
| 144 | Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 349-357.e2. | 0.2 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Development of colorectal cancer predicts increased risk of subsequent hepatocellular carcinoma in patients with alcoholic liver disease: case-control and cohort study. <i>Scientific Reports</i> , 2019, 9, 3236. | 1.6 | 1 |
| 146 | Alpha-fetoprotein for Diagnosis, Prognosis, and Transplant Selection. <i>Seminars in Liver Disease</i> , 2019, 39, 163-177. | 1.8 | 45 |
| 147 | Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision tree analysis after propensity score matching. <i>Hepatology Research</i> , 2019, 49, 919-928. | 1.8 | 42 |
| 148 | Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2019, 26, 893-899. | 1.0 | 25 |
| 149 | Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis. <i>Hepatology</i> , 2019, 69, 2533-2545. | 3.6 | 115 |
| 150 | Hepatocellular Carcinoma: Current Imaging Modalities for Diagnosis and Prognosis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 934-950. | 1.1 | 46 |
| 151 | Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. <i>Liver Cancer</i> , 2019, 8, 312-325. | 4.2 | 88 |
| 152 | Prognostic significance of minimal hepatic encephalopathy in patients with liver cirrhosis in Japan: A propensity score matching analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1809-1816. | 1.4 | 17 |
| 153 | Stratification of risk of recurrence after curative-intent treatment for small hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 649-650. | 0.7 | 1 |
| 154 | Late-Evening Carbohydrate and Branched-Chain Amino Acid Snacks Improve the Nutritional Status of Patients Undergoing Hepatectomy Based on Bioelectrical Impedance Analysis of Body Composition. <i>Gastrointestinal Tumors</i> , 2019, 6, 81-91. | 0.3 | 5 |
| 155 | Serum Zinc Level Classification System: Usefulness in Patients with Liver Cirrhosis. <i>Journal of Clinical Medicine</i> , 2019, 8, 2057. | 1.0 | 10 |
| 156 | Combined albumin-bilirubin grade and Mac-2 binding protein glycosylation isomer as a useful predictor in compensated liver cirrhosis. <i>Medicine (United States)</i> , 2019, 98, e18366. | 0.4 | 4 |
| 157 | Surveillance of hepatocellular carcinoma by medical imaging. <i>Quantitative Imaging in Medicine and Surgery</i> , 2019, 9, 1904-1910. | 1.1 | 9 |
| 158 | Assessment of Preoperative Liver Function for Surgical Decision Making in Patients with Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 447-456. | 4.2 | 42 |
| 159 | The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis. <i>Medicine (United States)</i> , 2019, 98, e15066. | 0.4 | 8 |
| 160 | Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-stage Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 1983-1994. | 3.6 | 127 |
| 161 | Ischemic complications after percutaneous radiofrequency ablation of liver tumors: Liver volume loss and recovery. <i>Hepatology Research</i> , 2019, 49, 453-461. | 1.8 | 4 |
| 162 | Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1066-1073. | 1.4 | 40 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Sorafenib: key lessons from over 10 years of experience. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 177-189. | 1.1 | 72 |
| 164 | Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. <i>Cancer Treatment Reviews</i> , 2019, 72, 28-36. | 3.4 | 342 |
| 165 | Radiofrequency ablation following artificial ascites and pleural effusion creation may improve outcomes for hepatocellular carcinoma in high-risk locations. <i>Abdominal Radiology</i> , 2019, 44, 1141-1151. | 1.0 | 19 |
| 166 | Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C. <i>PLoS ONE</i> , 2019, 14, e0208858. | 1.1 | 4 |
| 167 | Huge Hepatocellular Carcinoma Treated with Radical Hepatectomy after Drug-eluting Bead Transarterial Chemoembolization. <i>Internal Medicine</i> , 2019, 58, 1103-1110. | 0.3 | 2 |
| 168 | Liver resection for recurrent hepatocellular carcinoma after radiofrequency ablation therapy. <i>Hepatology Research</i> , 2019, 49, 432-440. | 1.8 | 17 |
| 169 | Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 75-84. | 1.8 | 105 |
| 170 | Severe Colitis Caused by Hepatic Arterial Infusion Chemotherapy with Cisplatin for Hepatocellular Carcinoma. <i>Internal Medicine</i> , 2020, 59, 69-75. | 0.3 | 2 |
| 171 | Liver Resection Versus Embolization for Recurrent Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2020, 44, 232-240. | 0.8 | 12 |
| 172 | Radiofrequency ablation for hepatocellular carcinoma: Clinical value of ultrasoundâ€œultrasound overlay fusion for optimal ablation and local controllability. <i>Hepatology Research</i> , 2020, 50, 67-74. | 1.8 | 14 |
| 173 | Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib. <i>Hepatology Research</i> , 2020, 50, 137-143. | 1.8 | 19 |
| 174 | Improved Local Tumor Control and Survival Rates by Obtaining a 3D-Safety Margin in Superselective Transarterial Chemoembolization for Small Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 423-433. | 0.9 | 9 |
| 175 | Diagnostic performance of a minimized protocol of non-contrast MRI for hepatocellular carcinoma surveillance. <i>Abdominal Radiology</i> , 2020, 45, 211-219. | 1.0 | 15 |
| 176 | Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma. <i>Hepatology Research</i> , 2020, 50, 365-373. | 1.8 | 8 |
| 177 | Hepatocellular carcinoma occurrence does not differ between interferonâ€œbased and interferonâ€œfree treatment with liver histological assessment. <i>Hepatology Research</i> , 2020, 50, 313-320. | 1.8 | 9 |
| 178 | Liver Resection for Multiple Hepatocellular Carcinomas. <i>Annals of Surgery</i> , 2020, 272, 145-154. | 2.1 | 61 |
| 179 | Evaluation of Contrast-enhanced US LI-RADS version 2017: Application on 2020 Liver Nodules in Patients with Hepatitis B Infection. <i>Radiology</i> , 2020, 294, 299-307. | 3.6 | 73 |
| 180 | Microvascular Invasion and a Size Cutoff Value of 2 cm Predict Long-Term Oncological Outcome in Multiple Hepatocellular Carcinoma: Reappraisal of the American Joint Committee on Cancer Staging System and Validation Using the Surveillance, Epidemiology, and End-Results Database. <i>Liver Cancer</i> , 2020, 9, 156-166. | 4.2 | 32 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Resection or radiofrequency ablation for hepatocellular carcinoma? Assessment of validity of current studies, meta-analyses and their influence on guidelines. <i>Hpb</i> , 2020, 22, 1206-1215. | 0.1 | 1 |
| 182 | Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. <i>Liver Cancer</i> , 2020, 9, 596-612. | 4.2 | 10 |
| 183 | Clinical outcomes of direct-acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment. <i>Hepatology Research</i> , 2020, 50, 1118-1127. | 1.8 | 15 |
| 184 | The Early Decline of α -Fetoprotein and Des- γ -Carboxy Prothrombin Predicts the Response of Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma Patients. <i>Gastrointestinal Tumors</i> , 2020, 7, 83-92. | 0.3 | 6 |
| 185 | The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia. <i>BMC Gastroenterology</i> , 2020, 20, 215. | 0.8 | 18 |
| 186 | Alteration of contrast enhanced ultrasound (CEUS) of hepatocellular carcinoma in patients with cirrhosis and transjugular intrahepatic portosystemic shunt (TIPS). <i>Scientific Reports</i> , 2020, 10, 20682. | 1.6 | 7 |
| 187 | Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals. <i>PLoS ONE</i> , 2020, 15, e0237475. | 1.1 | 1 |
| 188 | Clinical Role of Newly Developed ALBI and mALBI Grades for Treatment of Hepatocellular Carcinoma. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 7178. | 1.3 | 2 |
| 189 | Computational quantitative measures of Gd-EOB-DTPA enhanced MRI hepatobiliary phase images can predict microvascular invasion of small HCC. <i>European Journal of Radiology</i> , 2020, 133, 109361. | 1.2 | 7 |
| 190 | Liver resection of hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guideline recommendations: Results from a high-volume liver surgery center in East Asia. <i>Journal of Surgical Oncology</i> , 2020, 122, 1587-1594. | 0.8 | 16 |
| 191 | Relationship between outcomes and relative dose intensity of lenvatinib treatment in patients with advanced hepatocellular carcinoma. <i>Liver Research</i> , 2020, 4, 199-205. | 0.5 | 7 |
| 192 | Novel Prognostic Implications of Methylated RNA and Demethylases in Resected HCC and Background Liver Tissue. <i>Anticancer Research</i> , 2020, 40, 6665-6676. | 0.5 | 5 |
| 193 | Biomarkers in Hepatocellular Carcinoma: Current Status and Future Perspectives. <i>Biomedicines</i> , 2020, 8, 576. | 1.4 | 37 |
| 194 | Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade. <i>Liver Cancer</i> , 2020, 9, 518-528. | 4.2 | 22 |
| 195 | Prognostic Significance of Treatment Strategies for the Recurrent Hepatocellular Carcinomas After Radical Resection. <i>In Vivo</i> , 2020, 34, 1265-1270. | 0.6 | 3 |
| 196 | Acute kidney injury after multiphase imaging for lesions detected on hepatocellular carcinoma surveillance in patients with cirrhosis. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000394. | 1.1 | 2 |
| 197 | <i>Wisteria floribunda</i> Agglutinin-Positive Mac-2 Binding Protein but not α -fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3640. | 1.8 | 5 |
| 198 | A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus. <i>OMICS A Journal of Integrative Biology</i> , 2020, 24, 415-423. | 1.0 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Progress and prospects of biomarkers in early-stage primary liver cancer (Review). <i>International Journal of Oncology</i> , 2020, 57, 54-66. | 1.4 | 43 |
| 200 | High C-reactive protein/albumin ratio associated with reduced survival due to advanced stage of intrahepatic cholangiocarcinoma. <i>BioScience Trends</i> , 2020, 14, 304-309. | 1.1 | 12 |
| 201 | Altered glycosylation associated with dedifferentiation of hepatocellular carcinoma: a lectin microarray-based study. <i>BMC Cancer</i> , 2020, 20, 192. | 1.1 | 26 |
| 202 | Ablation for hepatocellular carcinoma: beyond the standard indications. <i>Medical Oncology</i> , 2020, 37, 23. | 1.2 | 7 |
| 203 | Circulating biomarkers for early detection of hepatocellular carcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093173. | 1.4 | 26 |
| 204 | Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort. <i>Cancers</i> , 2020, 12, 452. | 1.7 | 20 |
| 205 | Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. <i>Liver International</i> , 2020, 40, 968-976. | 1.9 | 51 |
| 206 | Impact of Adverse Events on the Progression-Free Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. <i>Drugs - Real World Outcomes</i> , 2020, 7, 141-149. | 0.7 | 33 |
| 207 | Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 307-319. | 1.8 | 310 |
| 208 | Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1595-1601. | 1.4 | 18 |
| 209 | Grip Strength: A Useful Marker for Composite Hepatic Events in Patients with Chronic Liver Diseases. <i>Diagnostics</i> , 2020, 10, 238. | 1.3 | 14 |
| 210 | Quantification of liver extracellular volume using dual-energy CT: utility for prediction of liver-related events in cirrhosis. <i>European Radiology</i> , 2020, 30, 5317-5326. | 2.3 | 21 |
| 211 | Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. <i>PLoS ONE</i> , 2020, 15, e0231828. | 1.1 | 42 |
| 212 | Utility of serological tumor biomarkers for surveillance of hepatocellular carcinoma in patients undergoing dialysis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1097-1103. | 0.4 | 4 |
| 213 | Microscopic portal vein invasion is a powerful predictor of prognosis in patients with hepatocellular carcinoma who have undergone liver resection. <i>Journal of Surgical Oncology</i> , 2021, 123, 222-235. | 0.8 | 10 |
| 214 | Prognostic nomograms and risk classifications of outcomes in very early-stage hepatocellular carcinoma patients after hepatectomy. <i>European Journal of Surgical Oncology</i> , 2021, 47, 681-689. | 0.5 | 10 |
| 215 | Sphingosine-1-phosphate Receptor-1 Promotes Vascular Invasion and EMT in Hepatocellular Carcinoma. <i>Journal of Surgical Research</i> , 2021, 259, 200-210. | 0.8 | 15 |
| 216 | Prediction of the prognosis of advanced hepatocellular carcinoma by <i>TERT</i> promoter mutations in circulating tumor DNA. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1118-1125. | 1.4 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis. <i>Oncology</i> , 2021, 99, 518-527. | 0.9 | 5 |
| 218 | Therapeutic Guidelines for Patients with Liver Cancer from the Perspective of Radiation Oncologists. , 2021, , 155-168. | | 0 |
| 219 | Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , 2021, 10, 126-136. | 4.2 | 6 |
| 220 | Predicting Therapeutic Efficacy of Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound. <i>Diagnostics</i> , 2021, 11, 291. | 1.3 | 7 |
| 221 | Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment. <i>Journal of Viral Hepatitis</i> , 2021, 28, 787-794. | 1.0 | 7 |
| 222 | A Pre-Operative Prognostic Score for Patients With Advanced Hepatocellular Carcinoma Who Underwent Resection. <i>Frontiers in Oncology</i> , 2021, 11, 569515. | 1.3 | 1 |
| 223 | Liver resection in elderly patients with hepatocellular carcinoma: age does matter. <i>Updates in Surgery</i> , 2021, 73, 1371-1380. | 0.9 | 5 |
| 224 | Laparoscopic liver resection versus percutaneous radiofrequency ablation for small hepatocellular carcinoma. <i>Hpb</i> , 2021, 23, 533-537. | 0.1 | 15 |
| 225 | Serum Laminin β 2 Monomer as a Diagnostic and Predictive Biomarker for Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 74, 760-775. | 3.6 | 21 |
| 226 | CT-Guided ^{125}I Brachytherapy in the Treatment of Hepatocellular Carcinoma Refractory to Conventional Transarterial Chemoembolization: A Pilot Study. <i>Cancer Management and Research</i> , 2021, Volume 13, 3317-3326. | 0.9 | 4 |
| 227 | Clinical Management of Liver Cancer in India and Other Developing Nations: A Focus on Radiation Based Strategies. <i>Oncology and Therapy</i> , 2021, 9, 273-295. | 1.0 | 2 |
| 228 | Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response. <i>Hepatology Communications</i> , 2021, 5, 1290-1299. | 2.0 | 12 |
| 229 | Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. <i>Hepatology Research</i> , 2021, 51, 880-889. | 1.8 | 15 |
| 230 | Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. <i>Liver Cancer</i> , 2021, 10, 181-223. | 4.2 | 307 |
| 231 | Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. <i>Hepatology Research</i> , 2021, 51, 860-869. | 1.8 | 8 |
| 232 | Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals. <i>Liver Cancer</i> , 2021, 10, 309-319. | 4.2 | 16 |
| 233 | Magnetic resonance elastography-based prediction of hepatocellular carcinoma recurrence after curative resection. <i>Surgery</i> , 2021, 170, 167-172. | 1.0 | 8 |
| 234 | Impact of board certification system and adherence to the clinical practice guidelines for liver cancer on post-hepatectomy risk-adjusted mortality rate in Japan: A questionnaire survey of departments registered with the National Clinical Database. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 801-811. | 1.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Impact of modified albuminâ€“bilirubin grade on survival in patients with HCC who received lenvatinib. Scientific Reports, 2021, 11, 14474. | 1.6 | 13 |
| 236 | Retrospective evaluation of the effect of Ninjinâ€™yoeito in hepatocellular carcinoma patients treated with lenvatinib. Surgery Today, 2022, 52, 441-448. | 0.7 | 4 |
| 237 | Transmediastinal, intrapericardial inferior vena cava approach based on anatomical landmarks for hepatectomy using total hepatic vascular exclusion. Langenbeck's Archives of Surgery, 2021, , 1. | 0.8 | 0 |
| 238 | What is the optimal surgical treatment for hepatocellular carcinoma beyond the debate between anatomical versus non-anatomical resection?. Surgery Today, 2022, 52, 871-880. | 0.7 | 2 |
| 239 | Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. Journal of the Formosan Medical Association, 2021, , . | 0.8 | 10 |
| 240 | Progress of MRI Radiomics in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 698373. | 1.3 | 24 |
| 241 | Postoperative controlling nutritional status score is an independent risk factor of survival for patients with small hepatocellular carcinoma: a retrospectiveÂstudy. BMC Surgery, 2021, 21, 338. | 0.6 | 3 |
| 242 | Alteration of prognostic efficacy of albuminâ€“bilirubin grade and Childâ€Pugh score according to liver fibrosis in hepatocellular carcinoma patients with Childâ€Pugh A following hepatectomy. Annals of Gastroenterological Surgery, 2022, 6, 127-134. | 1.2 | 6 |
| 243 | Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. Hepatology Communications, 2021, 5, 1972-1986. | 2.0 | 24 |
| 244 | Prospective Multicenter Interventional Study of Surgical Resection for Liver Metastasis from Gastric Cancer: R0 Resection Rate, and Operative Morbidity and Mortality. Annals of Surgical Oncology, 2022, 29, 924-932. | 0.7 | 7 |
| 245 | Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO). Hepatobiliary Surgery and Nutrition, 2021, 10, 661-671. | 0.7 | 46 |
| 246 | Intra-arterial Chemotherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma. , 2021, , 171-187. | | 0 |
| 247 | Viral and Host Factors Affecting Disease Progression of Hepatitis B Virus Infection. , 2021, , 205-230. | | 0 |
| 248 | Medical Therapy of HCC. , 2016, , 489-512. | | 1 |
| 249 | Plateletâ€“lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis. European Journal of Gastroenterology and Hepatology, 2021, 32, 261-268. | 0.8 | 9 |
| 250 | L-carnitine reduces hospital admissions in patients with hepatic encephalopathy. European Journal of Gastroenterology and Hepatology, 2021, 32, 288-293. | 0.8 | 4 |
| 251 | HCC screening: assessment of an abbreviated non-contrast MRI protocol. European Radiology Experimental, 2019, 3, 49. | 1.7 | 37 |
| 252 | Hepatobiliary Tumors: Update on Diagnosis and Management. Journal of Clinical and Translational Hepatology, 2015, 3, 169-181. | 0.7 | 39 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 253 | Hepatocellular Carcinoma: State of the Art Imaging and Recent Advances. <i>Journal of Clinical and Translational Hepatology</i> , 2019, 7, 1-14. | 0.7 | 28 |
| 254 | Development of a nomogram for screening of hepatitis B virus-associated hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 106499-106510. | 0.8 | 5 |
| 255 | Liver transplantation for hepatocellular carcinoma from living-donor vs. deceased donor. <i>Hepatobiliary Surgery and Nutrition</i> , 2016, 5, 422-428. | 0.7 | 14 |
| 256 | Similar complication rates for irreversible electroporation and thermal ablation in patients with hepatocellular tumors. <i>Radiology and Oncology</i> , 2019, 53, 116-122. | 0.6 | 26 |
| 257 | Improvement of the primary efficacy of microwave ablation of malignant liver tumors by using a robotic navigation system. <i>Radiology and Oncology</i> , 2020, 54, 295-300. | 0.6 | 13 |
| 258 | Comparison of percutaneous radiofrequency ablation and CyberKnife [®] for initial solitary hepatocellular carcinoma: A pilot study. <i>World Journal of Gastroenterology</i> , 2015, 21, 13490. | 1.4 | 39 |
| 259 | Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study. <i>World Journal of Gastroenterology</i> , 2016, 22, 10219. | 1.4 | 18 |
| 260 | Management of sub-centimeter recurrent hepatocellular carcinoma after curative treatment: Current status and future. <i>World Journal of Gastroenterology</i> , 2018, 24, 5215-5222. | 1.4 | 22 |
| 261 | Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: Diverse global viewpoints. <i>World Journal of Gastroenterology</i> , 2020, 26, 393-403. | 1.4 | 29 |
| 262 | Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment. <i>Molecular and Clinical Oncology</i> , 2020, 12, 111-116. | 0.4 | 16 |
| 263 | Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma. <i>Oncology Letters</i> , 2020, 19, 2667-2676. | 0.8 | 7 |
| 264 | Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis. <i>Oncology Letters</i> , 2020, 20, 2257-2265. | 0.8 | 44 |
| 265 | Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 663-676. | 0.8 | 13 |
| 266 | High burden of hepatocellular carcinoma and viral hepatitis in Southern and Central Vietnam: Experience of a large tertiary referral center, 2010 to 2016. <i>World Journal of Hepatology</i> , 2018, 10, 116-123. | 0.8 | 13 |
| 267 | Efficacy of intra-arterial contrast-enhanced ultrasonography during transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2018, 10, 95-104. | 0.8 | 8 |
| 268 | How high is the inter-observer reproducibility in the LIRADS reporting system?. <i>Polish Journal of Radiology</i> , 2019, 84, 464-469. | 0.5 | 7 |
| 269 | High platelet count as a poor prognostic factor for liver cancer patients without cirrhosis. <i>BioScience Trends</i> , 2020, 14, 368-375. | 1.1 | 7 |
| 270 | Factors Associated With Detection and Survival of T1 Hepatocellular Carcinoma in the United States: National Cancer Database Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1210-1220. | 2.3 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 271 | Development of a prognostic scoring model for predicting the survival of elderly patients with hepatocellular carcinoma. PeerJ, 2020, 8, e8497. | 0.9 | 9 |
| 272 | A Case of Metastatic Hepatocellular Carcinoma of the Nasal Septum. Practica Otologica, 2015, 108, 859-863. | 0.0 | 0 |
| 273 | A Case of Metastatic Hepatocellular Carcinoma of the Nasal Septum. Practica Otologica, Supplement, 2016, 145, 98-99. | 0.0 | 0 |
| 275 | Hepatic Arterial Infusion Chemotherapy with Cisplatin for TACE-Refractory or -Ineligible Hepatocellular Carcinoma with Child-Pugh Score of 8 or Above. Hepatitis Monthly, 2017, 17, . | 0.1 | 0 |
| 276 | Liver: Oncology/Trauma. Clinical Gastroenterology, 2018, , 75-100. | 0.0 | 0 |
| 277 | Effects of Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma Using a Combination of Platinum Agents (Cisplatin plus Miriplatin): A Retrospective Comparison with Cisplatin Monotherapy. Open Journal of Radiology, 2018, 08, 260-273. | 0.1 | 0 |
| 278 | Assessing the characteristics and feasibility of preventing early mortality in patients with hepatocellular carcinoma. Turkish Journal of Gastroenterology, 2019, 30, 541-548. | 0.4 | 3 |
| 279 | Evaluating the liver function of patients with hepatocellular carcinoma. Hepatology Research, 2021, 51, 1095-1096. | 1.8 | 1 |
| 280 | <p><p>Can Immediately Treating Subcentimeter Hepatocellular Carcinoma Improve the Survival of Patients?</p>. Journal of Hepatocellular Carcinoma, 2020, Volume 7, 377-384. | 1.8 | 5 |
| 281 | Comparison of the surgical outcomes in patients with synchronous versus metachronous multiple hepatocellular carcinoma. BioScience Trends, 2020, 14, 415-421. | 1.1 | 2 |
| 282 | Determinants of pain in advanced HCC patients receiving hepatic artery infusion chemotherapy. Investigational New Drugs, 2021, 39, 394-399. | 1.2 | 3 |
| 283 | Role of Tumor Biomarkers in the Surveillance of Hepatocellular Carcinoma. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2021, 78, 284-288. | 0.2 | 1 |
| 285 | Autoantibody to GNAS in Early Detection of Hepatocellular Carcinoma: A Large-Scale Sample Study Combined with Verification in Serial Sera from HCC Patients. Biomedicines, 2022, 10, 97. | 1.4 | 3 |
| 286 | Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era. Oncology, 2022, 100, 65-73. | 0.9 | 3 |
| 287 | Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus. PLoS ONE, 2022, 17, e0262267. | 1.1 | 9 |
| 288 | Machine Learningâ€‘Based Personalized Prediction of Hepatocellular Carcinoma Recurrence After Radiofrequency Ablation. , 2022, 1, 29-37. | | 5 |
| 289 | Validation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment. World Journal of Gastroenterology, 2022, 28, 665-674. | 1.4 | 1 |
| 290 | The prominence of potential biomarkers in the diagnosis and management of hepatocellular carcinoma: Current scenario and future anticipation. Journal of Cellular Biochemistry, 2022, 123, 1607-1623. | 1.2 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 291 | Updates on the staging and treatment of hepatocellular carcinoma. , 2022, , 307-319. | | 0 |
| 292 | Prediction of Posthepatectomy Liver Failure with a Combination of Albumin-Bilirubin Score and Liver Resection Percentage. <i>Journal of the American College of Surgeons</i> , 2022, 234, 155-165. | 0.2 | 2 |
| 293 | Neutrophilâ€“lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 698-706. | 0.8 | 27 |
| 294 | Assessment of serum Talin-1 in liver cirrhosis and hepatocellular carcinoma. <i>Egyptian Liver Journal</i> , 2022, 12, . | 0.3 | 0 |
| 295 | Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy. <i>Cancer Reports</i> , 2022, 5, e1613. | 0.6 | 4 |
| 296 | Assessment of Liver Function With MRI: Where Do We Stand?. <i>Frontiers in Medicine</i> , 2022, 9, 839919. | 1.2 | 8 |
| 297 | Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1919-1938. | 0.8 | 15 |
| 298 | Deep learning radiomics for focal liver lesions diagnosis on long-range contrast-enhanced ultrasound and clinical factors. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 3213-3226. | 1.1 | 4 |
| 299 | Liver resection for large and huge hepatocellular carcinoma: Predictors of failure, recurrence patterns, and prognoses. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2023, 19, . | 0.7 | 2 |
| 300 | Genistein Produces Hepatoprotection through Modulating EGFR Expression and Phosphorylation in Experimental Fibrosis. <i>Journal of Liver</i> , 2016, 5, . | 0.3 | 1 |
| 301 | Surveillance for Hepatocellular Carcinoma Reduces Mortality: an Inverse Probability of Treatment Weighted Analysis. <i>Annals of Hepatology</i> , 2017, 16, 421-429. | 0.6 | 5 |
| 302 | METTL3 facilitates the progression of hepatocellular carcinoma by modulating the m6A level of USP7.. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 13423-13437. | 0.0 | 1 |
| 303 | Comparison of anatomical thermal ablation and routine thermal ablation for hepatocellular carcinomaâ€“50 mm: A PROPENSITY SCORE MATCHING. <i>Hepatology Research</i> , 2022, , . | 1.8 | 2 |
| 304 | Methyltransferase-like 3 Aggravates HCC Development via Mediating N6-Methyladenosine of Ubiquitin-Specific Protease 7. <i>Journal of Oncology</i> , 2022, 2022, 1-9. | 0.6 | 2 |
| 305 | Chronic liver disease questionnaire to manage patients with chronic liver diseases. <i>Hepatology Research</i> , 2022, , . | 1.8 | 0 |
| 306 | C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. <i>Scientific Reports</i> , 2022, 12, 8421. | 1.6 | 4 |
| 307 | Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2022, 14, 1190-1199. | 0.8 | 3 |
| 308 | Interrater reliability and agreement of the liver imaging reporting and data system (LI-RADS) v2018 for the evaluation of hepatic lesions. <i>Polish Journal of Radiology</i> , 2022, 87, 316-324. | 0.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 309 | Long-term outcomes of living donor liver transplantation, hepatic resection, and local therapy for hepatocellular carcinoma with three or more nodules in a single institute. <i>JGH Open</i> , 0, . | 0.7 | 0 |
| 310 | Application of albumin-bilirubin grade and platelet count to indocyanine green-based criteria for hepatectomy: Predicting impaired liver function and postoperative outcomes of hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 0, . | 0.8 | 0 |
| 311 | Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2022, 14, 1480-1494. | 0.8 | 0 |
| 312 | Treatment Benefits and Side Effects of Transarterial Chemoembolization with Drug-Eluting Bead Microspheres (DEB-TACE) in Hepatocellular Carcinoma Patients with Conventional TACE Resistance: A Retrospective Study. <i>Iranian Journal of Radiology</i> , 2022, 19, . | 0.1 | 1 |
| 313 | Benefits of tailored hepatocellular carcinoma screening in patients with cirrhosis on cancer-specific and overall mortality: A modeling approach. <i>Hepatology Communications</i> , 2022, 6, 2964-2974. | 2.0 | 1 |
| 314 | Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 5075. | 1.0 | 8 |
| 315 | Cutoff values of protein induced by vitamin K absence or antagonist II for diagnosing hepatocellular carcinoma. <i>Medicine (United States)</i> , 2022, 101, e30936. | 0.4 | 2 |
| 316 | Nomogram-based development and evaluation for predictions of 30-day and 1-year survival in patients with spontaneously ruptured hepatocellular carcinoma. <i>BMC Cancer</i> , 2022, 22, . | 1.1 | 1 |
| 317 | Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi-center phase I trial. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 1 |
| 318 | Hepatocellular carcinoma complicated with huge posterior pancreas head lymph node metastasis and primary renal carcinoma: A case report. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 0 |
| 319 | New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study. <i>Cancer Medicine</i> , 2023, 12, 6980-6993. | 1.3 | 8 |
| 320 | Tumor stiffness measurement using magnetic resonance elastography can predict recurrence and survival after curative resection of hepatocellular carcinoma. <i>Surgery</i> , 2023, 173, 450-456. | 1.0 | 1 |
| 321 | Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. <i>Cancer Medicine</i> , 2023, 12, 7772-7783. | 1.3 | 8 |
| 322 | Patients with Chronic Liver Disease under Surveillance for Hepatocellular Carcinoma Have a Favorable Long-Term Outcome for Pancreatic Cancer Due to Early Diagnosis and High Resection Rate. <i>Cancers</i> , 2023, 15, 561. | 1.7 | 0 |
| 323 | Prognostic value of des-carboxyprothrombin in patients with AFP-negative HCC treated with TACE. <i>Oncology Letters</i> , 2022, 25, . | 0.8 | 0 |
| 324 | Quantitative analysis of artificial intelligence on liver cancer: A bibliometric analysis. <i>Frontiers in Oncology</i> , 0, 13, . | 1.3 | 5 |
| 325 | Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines). <i>Hepatology Research</i> , 2023, 53, 383-390. | 1.8 | 39 |
| 326 | EVALUATION OF DIAGNOSTIC VALIDITY OF PIVKA-II FOR DIAGNOSIS OF HEPATOCELLULAR CARCINOMA IN PATIENTS OF CIRRHOSIS WITH LIVER NODULES PRESENTED IN A TERTIARY CARE HOSPITAL OF LAHORE. , 2023, 20, . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 327 | Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2023, 23, . | 0.8 | 0 |
| 328 | Hepatocellular Carcinoma with Hepatic Vein and Inferior Vena Cava Invasion. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 813-819. | 0.4 | 0 |
| 329 | Nomogram to predict the prognosis of patients with AFP-negative hepatocellular carcinoma undergoing chemotherapy: A SEER based study. <i>Medicine (United States)</i> , 2023, 102, e33319. | 0.4 | 0 |
| 330 | Usefulness of PIVKA-II for monitoring after liver transplantation in patients with hepatocellular carcinoma. <i>Scientific Reports</i> , 2023, 13, . | 1.6 | 1 |